Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 29.
doi: 10.1007/s11604-025-01842-1. Online ahead of print.

Pharmacokinetics and safety of gadopiclenol in Japanese healthy volunteers

Takashi Eto  1 , Toshiaki Taoka  2 , Mathieu Felices  3 , Camille Pitrou  4
Affiliations

Pharmacokinetics and safety of gadopiclenol in Japanese healthy volunteers

Takashi Eto et al. Jpn J Radiol. .

Abstract

Purpose: The aim of this study was to evaluate the pharmacokinetics and safety of gadopiclenol in Japanese healthy volunteers. A population-based pharmacokinetic approach was used to compare pharmacokinetic parameters with a non-Japanese adult population.

Materials and methods: In this double-blind, placebo-controlled phase I study, Japanese healthy volunteers were randomized to receive gadopiclenol (at 0.025, 0.05, or 0.1 mmol/kg) or a placebo. Blood and urine samples were collected up to 24- and 48-h post-administration, respectively. The pharmacokinetic profile of gadopiclenol was evaluated using standard non-compartmental analysis. Adverse events (AEs) were collected during the whole study period.

Results: Overall, 27 participants were randomized (median [range] age: 22 [20-43] years; 52% male): 18 received gadopiclenol (6 in each dose group), and 9 received the placebo. The mean systemic exposure of gadopiclenol increased proportionally with the injected dose (area under the curve [AUC]: 215-1034 μg/mL.h) and was comparable between the three dose groups when normalized to dose (AUC/dose: 182-189 μg/mL/g.h) and to non-Japanese (168-183 μg/mL.h). The mean terminal half-life (1.43-1.86 h), and the distribution volume (11.3-15.2 L) were also similar to those of non-Japanese healthy volunteers (1.50-1.73 h and 13.0-15.5 L, respectively). The mean fraction of gadopiclenol excreted in urine was between 87 and 95%, depending on the administered dose. Most of gadopiclenol (median of 95.7%) was excreted within 24 h after administration. The mean total clearance was comparable between the different administered doses (5.3-5.6 L/h) and similar to the mean renal clearance. No gadopiclenol-related AEs were reported.

Conclusions: The pharmacokinetic profile of gadopiclenol is similar in Japanese and non-Japanese healthy volunteers. The population pharmacokinetic analysis showed no significant ethnic disparities between these two populations and suggested that no dose adjustment was required for Japanese patients. Gadopiclenol had a very good tolerability in Japanese healthy volunteers with no adverse reactions reported.

Keywords: Gadopiclenol; Macrocyclic; Magnetic resonance imaging; Pharmacokinetics; Safety.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: T.T. and T.E. reported no relevant conflicts of interest. C.P. is employed by Guerbet. Ethical approval: This study was approved by the local ethics committee and complied with the 1964 Declaration of Helsinki. Informed consent: All patients gave informed consent to participate in the study.

References

    1. Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20(8):653–70.
    1. Hemond CC, Bakshi R. Magnetic resonance imaging in multiple sclerosis. Cold Spring Harb Perspect Med. 2018. https://doi.org/10.1101/cshperspect.a028969 . - DOI
    1. Bonm AV, Ritterbusch R, Throckmorton P, Graber JJ. Clinical imaging for diagnostic challenges in the management of gliomas: a review. J Neuroimaging. 2020;30(2):139–45.
    1. Mitchell DK, Kwon HJ, Kubica PA, Huff WX, O’Regan R, Dey M. Brain metastases: an update on the multi-disciplinary approach of clinical management. Neurochirurgie. 2022;68(1):69–85.
    1. Niendorf E, Spilseth B, Wang X, Taylor A. Contrast enhanced MRI in the diagnosis of HCC. Diagnostics. 2015;5(3):383–98.

LinkOut - more resources